JP4981231B2 - レトロウイルスパッケージング細胞での発現のためのコドン最適化 - Google Patents

レトロウイルスパッケージング細胞での発現のためのコドン最適化 Download PDF

Info

Publication number
JP4981231B2
JP4981231B2 JP2001577501A JP2001577501A JP4981231B2 JP 4981231 B2 JP4981231 B2 JP 4981231B2 JP 2001577501 A JP2001577501 A JP 2001577501A JP 2001577501 A JP2001577501 A JP 2001577501A JP 4981231 B2 JP4981231 B2 JP 4981231B2
Authority
JP
Japan
Prior art keywords
gag
pol
retroviral
nucleotide sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001577501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508808A (ja
JP2004508808A5 (cg-RX-API-DMAC7.html
Inventor
キングズマン，アラン・ジョン
キム，ナリー
コツォポウロウ，エカテリーニ
ロール，ジョナサン
ミトロファノス，キリヤコス・アンドルー
Original Assignee
オックスフォード バイオメディカ（ユーケー）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オックスフォード バイオメディカ（ユーケー）リミテッド filed Critical オックスフォード バイオメディカ（ユーケー）リミテッド
Publication of JP2004508808A publication Critical patent/JP2004508808A/ja
Publication of JP2004508808A5 publication Critical patent/JP2004508808A5/ja
Application granted granted Critical
Publication of JP4981231B2 publication Critical patent/JP4981231B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
JP2001577501A 2000-04-19 2001-04-18 レトロウイルスパッケージング細胞での発現のためのコドン最適化 Expired - Lifetime JP4981231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0009760.0A GB0009760D0 (en) 2000-04-19 2000-04-19 Method
GB0009760.0 2000-04-19
PCT/GB2001/001784 WO2001079518A2 (en) 2000-04-19 2001-04-18 Codon optimisation for expression in retrovirus packaging cells

Publications (3)

Publication Number Publication Date
JP2004508808A JP2004508808A (ja) 2004-03-25
JP2004508808A5 JP2004508808A5 (cg-RX-API-DMAC7.html) 2008-04-03
JP4981231B2 true JP4981231B2 (ja) 2012-07-18

Family

ID=9890278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001577501A Expired - Lifetime JP4981231B2 (ja) 2000-04-19 2001-04-18 レトロウイルスパッケージング細胞での発現のためのコドン最適化

Country Status (14)

Country Link
US (3) US20050042234A1 (cg-RX-API-DMAC7.html)
EP (2) EP2194137B1 (cg-RX-API-DMAC7.html)
JP (1) JP4981231B2 (cg-RX-API-DMAC7.html)
CN (2) CN101024845B (cg-RX-API-DMAC7.html)
AT (1) ATE462796T1 (cg-RX-API-DMAC7.html)
AU (1) AU4861901A (cg-RX-API-DMAC7.html)
CA (1) CA2404129A1 (cg-RX-API-DMAC7.html)
CY (1) CY1110123T1 (cg-RX-API-DMAC7.html)
DE (1) DE60141690D1 (cg-RX-API-DMAC7.html)
DK (2) DK2194137T3 (cg-RX-API-DMAC7.html)
ES (2) ES2618508T3 (cg-RX-API-DMAC7.html)
GB (1) GB0009760D0 (cg-RX-API-DMAC7.html)
PT (1) PT1278878E (cg-RX-API-DMAC7.html)
WO (1) WO2001079518A2 (cg-RX-API-DMAC7.html)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US9738907B2 (en) 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
DK2348119T3 (en) 2002-02-01 2017-08-21 Oxford Biomedica (Uk) Ltd Polycistronic lentiviral vector
WO2003066810A2 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
WO2005118809A2 (en) * 2004-04-29 2005-12-15 The University Of North Carolina At Chapel Hill Methods and compositions for enhancing cell adhesion properties
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
JP5615271B2 (ja) 2008-06-18 2014-10-29 オックスフォード バイオメディカ（ユーケー）リミテッド ウイルス精製法
ES2536791T3 (es) 2010-05-28 2015-05-28 Oxford Biomedica (Uk) Ltd Administración de vectores lentivirales al cerebro
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
CN105408352B (zh) 2013-04-18 2020-01-14 泰莱托恩基金会 通过双重aav载体有效递送大基因
EP3060670B1 (en) 2013-10-24 2019-07-10 Ospedale San Raffaele S.r.l. Method
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
HRP20191468T1 (hr) 2014-09-15 2019-11-29 Molmed Spa Kimerni antigenski receptori
GB201418965D0 (cg-RX-API-DMAC7.html) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
GB201604146D0 (en) 2016-03-10 2016-04-27 Nightstarx Ltd Prenylation assay
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
EP3318285A1 (en) 2016-11-08 2018-05-09 Oxford University Innovation Limited Treatment of eye disease
WO2018099933A1 (en) 2016-12-01 2018-06-07 Nestec S.A. Methods of modulating fam46a
CN108130333A (zh) * 2016-12-01 2018-06-08 上海泽润生物科技有限公司 重组脊髓灰质炎ⅰ型病毒样颗粒
EP3375876A1 (en) 2017-03-13 2018-09-19 Evonetix Ltd Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures
WO2018167486A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
CN110475865A (zh) 2017-03-31 2019-11-19 雀巢产品有限公司 调节ank1的方法
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
WO2018193119A1 (en) 2017-04-21 2018-10-25 Ospedale San Raffaele S.R.L. Gene therapy
TWI835730B (zh) 2017-04-24 2024-03-21 義大利聖拉斐爾醫院 Ｔｃｒ及肽
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
EP3697923A1 (en) 2017-10-17 2020-08-26 Nightstarx Limited Prenylation assay
JP7477448B2 (ja) 2017-11-21 2024-05-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ａｌｋを調節する方法
GB201720948D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
WO2019134866A1 (en) 2018-01-03 2019-07-11 Molmed Spa Chimeric antigen receptors containing optimal spacer region
IL278016B2 (en) 2018-04-18 2025-03-01 Ucl Business Ltd Method for Enhancing the Suppressive Properties of Treg Cells
US20210228627A1 (en) 2018-05-15 2021-07-29 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
JP2021526361A (ja) 2018-05-17 2021-10-07 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ｎｋｘ６．３を調節する方法
US12304962B2 (en) 2018-05-30 2025-05-20 Glycostem Therapeutics B.V. CAR NK cells
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
GB201817821D0 (en) 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
US20230048166A1 (en) 2018-11-14 2023-02-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
GB201900687D0 (en) 2019-01-17 2019-03-06 King S College London Immunotherapeutic methods and compositions
US20220062340A1 (en) 2018-12-19 2022-03-03 King's College London Immunotherapeutic methods and compositions
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
US20220175962A1 (en) 2019-03-10 2022-06-09 Sio Gene Therapies Inc. Gene therapy compositions and methods for treating parkinson's disease
GB201905301D0 (en) 2019-04-15 2019-05-29 Ospedale San Raffaele Srl Gene therapy
GB201907493D0 (en) 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
GB201912515D0 (en) 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
CA3152525A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
JP7759318B2 (ja) 2019-11-12 2025-10-23 オックスフォード バイオメディカ（ユーケー）リミテッド 産生系
US20240052366A1 (en) 2020-02-13 2024-02-15 Oxford Biomedica (Uk) Limited Production of Lentiviral Vectors
US20230138428A1 (en) 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
JP2023516493A (ja) 2020-03-13 2023-04-19 オックスフォード バイオメディカ（ユーケー）リミテッド レンチウイルスベクター
CA3178308A1 (en) 2020-03-31 2021-10-07 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
GB202007169D0 (en) 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
JP2023540705A (ja) 2020-08-28 2023-09-26 サナ バイオテクノロジー，インコーポレイテッド 修飾された抗ウイルス結合剤
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202018657D0 (en) 2020-11-26 2021-01-13 Ospedale San Raffaele Srl Agents and methods for increasing liver immune response
CN112430582B (zh) * 2020-12-04 2022-05-03 北京艺妙神州医药科技有限公司 一种慢病毒稳定包装细胞系及其制备方法
EP4267601A1 (en) 2020-12-23 2023-11-01 Quell Therapeutics Limited Inducible signalling protein
JP2024503027A (ja) 2021-01-11 2024-01-24 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８標的ウイルスベクターの使用方法
US20240139319A1 (en) 2021-02-01 2024-05-02 Epsilen Bio S.R.L Gene silencing
AU2022220842A1 (en) 2021-02-15 2023-09-21 Consiglio Nazionale Delle Ricerche Epigenetic silencing for treatment of cancer
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
GB202102832D0 (en) * 2021-02-26 2021-04-14 Ip2Ipo Innovations Ltd Retroviral vectors
IL308356A (en) 2021-05-12 2024-01-01 Fond Telethon Vector system
CA3219487A1 (en) 2021-05-28 2022-12-01 Richard C. Mulligan Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
WO2023047100A1 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
WO2023047098A2 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-p75ntr chimeric antigen receptor
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023118878A1 (en) 2021-12-22 2023-06-29 Quell Therapeutics Limited Constitutive cytokine receptors
EP4209511A1 (en) 2022-01-05 2023-07-12 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies amd chimeric antigen receptors
WO2023131657A1 (en) 2022-01-05 2023-07-13 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies and chimeric antigen receptors
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4269426A1 (en) 2022-04-29 2023-11-01 Ospedale San Raffaele S.r.l. Gene therapy
EP4551253A1 (en) 2022-07-08 2025-05-14 Ospedale San Raffaele S.r.l. Transgene cassettes
EP4303226A1 (en) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgene cassettes and epigenetic silencers for the treatment of disorders
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024033544A1 (en) 2022-08-12 2024-02-15 Ospedale San Raffaele S.R.L. Deglycosylation of native glycoproteins expressed on a tumor cell surface
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4615492A1 (en) 2022-11-08 2025-09-17 Ospedale San Raffaele S.r.l. Polynucleotide and vector
CN120882745A (zh) 2022-11-11 2025-10-31 圣拉斐尔医院有限责任公司 Cdh17 car
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
EP4651887A1 (en) 2023-01-16 2025-11-26 Ospedale San Raffaele S.r.l. T-cell receptors
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
TW202436337A (zh) 2023-01-23 2024-09-16 漢諾威醫學院 嵌合抗原受體
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
CN120981564A (zh) 2023-03-17 2025-11-18 圭尔医疗有限公司 调节性t细胞疗法
WO2024194223A2 (en) 2023-03-17 2024-09-26 Ospedale San Raffaele S.R.L. Gene therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
CN121219020A (zh) 2023-03-22 2025-12-26 圣拉斐尔医院有限责任公司 基因疗法
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
GB202307366D0 (en) 2023-05-17 2023-06-28 Ospedale San Raffaele Srl Vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024261480A1 (en) 2023-06-21 2024-12-26 Quell Therapeutics Limited Constitutive cytokine receptors
WO2025003481A2 (en) 2023-06-28 2025-01-02 Ospedale San Raffaele S.R.L. T-cell receptors
WO2025032194A1 (en) 2023-08-08 2025-02-13 Ospedale San Raffaele S.R.L. T-cell receptors
GB202316264D0 (en) 2023-10-24 2023-12-06 Ospendale San Raffaele S R L Gene therapy
IT202300022191A1 (it) 2023-10-24 2025-04-24 Fond Telethon Ets Mezzi e metodi per la modifica genetica di uba1
WO2025109189A1 (en) 2023-11-24 2025-05-30 Ospedale San Raffaele S.R.L. Engineered regulatory t cells and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
EP4640830A1 (en) 2024-04-23 2025-10-29 Fondazione Telethon ETS Means and methods for safe and efficient gene editing in cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368882A1 (de) 1987-07-29 1990-05-23 BASF Lacke + Farben AG Kathodisch abscheidbare kunstharze enthaltende wässrige elektrotauchlackbäder und verfahren zur beschichtung elektrisch leitfähiger substrate
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
CA2092195C (en) 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
WO1996009400A1 (en) 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0859856A2 (en) 1995-11-08 1998-08-26 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6118001A (en) 1996-08-07 2000-09-12 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
IL132463A0 (en) * 1997-05-13 2001-03-19 Univ North Carolina Lentivirus - based gene transfer vectors
AU747609B2 (en) 1997-09-23 2002-05-16 Oxford Biomedica (Uk) Limited Expression of genes in hematopoietic stem cells in hischaemic conditions
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
ATE528405T1 (de) * 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6958226B1 (en) * 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
IL146090A0 (en) * 1999-04-26 2002-07-25 Leuven K U Res & Dev A synthetic gene for expression of a retroviral protein with wild type activity in eukaryotic cells
GB9923558D0 (en) * 1999-10-05 1999-12-08 Oxford Biomedica Ltd Producer cell

Also Published As

Publication number Publication date
JP2004508808A (ja) 2004-03-25
DK1278878T3 (da) 2010-06-28
US20100273996A1 (en) 2010-10-28
DK2194137T3 (en) 2017-03-20
CN101024845B (zh) 2013-01-16
EP1278878B1 (en) 2010-03-31
ATE462796T1 (de) 2010-04-15
US20080269473A1 (en) 2008-10-30
AU4861901A (en) 2001-10-30
EP1278878A2 (en) 2003-01-29
CN101024845A (zh) 2007-08-29
ES2618508T3 (es) 2017-06-21
EP2194137A3 (en) 2010-07-28
WO2001079518A3 (en) 2002-05-16
US20050042234A1 (en) 2005-02-24
EP2194137A2 (en) 2010-06-09
CA2404129A1 (en) 2001-10-25
CN1426477A (zh) 2003-06-25
PT1278878E (pt) 2010-05-31
GB0009760D0 (en) 2000-06-07
CN1254543C (zh) 2006-05-03
ES2343564T3 (es) 2010-08-04
DE60141690D1 (de) 2010-05-12
EP2194137B1 (en) 2016-12-21
CY1110123T1 (el) 2015-01-14
WO2001079518A2 (en) 2001-10-25
AU2001248619B2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
JP4981231B2 (ja) レトロウイルスパッケージング細胞での発現のためのコドン最適化
EP1895010B1 (en) Equine infectious anaemia virus (eiav) based vectors
JP4418536B2 (ja) レトロウイルスベクター
JP4436024B2 (ja) レンチウイルスの三重鎖ｄｎａ、並びにレンチウイルスの三重鎖ｄｎａを含有するベクター及び組換え細胞
JP4979851B2 (ja) 高いタイターで安全な組換えレンチウイルスベクターの作製方法
JP2003511039A (ja) レトロウイルスベクター産生用のプロデューサー細胞
US6969598B2 (en) Methods for producing high titre vectors and compositions used in such methods
JP2010227122A (ja) 高力価で安全な組換えレンチウイルスベクター作成の方法及び手段
JP2007510412A (ja) レトロウイルスベクター及びレンチウイルスベクター
JP2001517452A (ja) 機能的スプライス・ドナー部位及び機能的スプライス・アクセプター部位を含むレトロウイルスベクター
KR20010074493A (ko) 레트로바이러스 전달 시스템
JP2025129152A (ja) 産生系
WO2004033653A2 (en) Gene regulation with aptamer and modulator complexes for gene therapy
JP2002539797A (ja) 機能的および非機能的なスプライス供与部位ならびにスプライス受容部位を含むレトロウイルスベクター
AU2001248619C1 (en) Method
US20030143205A1 (en) Alphavirus expression systems
US20230151388A1 (en) Modified vectors for production of retrovirus
AU2001248619A1 (en) Method
GB2356200A (en) Hybrid viral vectors
AU5543700A (en) Siv-based packaging-defficient vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110803

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120327

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120420

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150427

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4981231

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term